Skip to content
10-Q

Quarterly Report

Viridian Therapeutics, Inc.\DE VRDN

0001590750-25-000012

← back to feed
Filed
Aug 6, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2025 · Aug 1, 2025 81.66M sh
Capex Q2 2025 · Jun 30, 2025 $128K
Capex Q2 2025 · Jun 30, 2024 $104K
Operating Cash Flow Q2 2025 · Jun 30, 2025 −$168.03M
Operating Cash Flow Q2 2025 · Jun 30, 2024 −$91.28M
Long Term Debt Q2 2025 · Jun 30, 2025 $12.35M
Long Term Debt Q2 2025 · Dec 31, 2024 $20.58M
Short Term Debt Q2 2025 · Jun 30, 2025 $8.44M
Short Term Debt Q2 2025 · Dec 31, 2024 $0
Stockholders Equity Q2 2025 · Jun 30, 2025 $515.17M
Stockholders Equity Q2 2025 · Mar 31, 2025 $604.47M
Stockholders Equity Q2 2025 · Dec 31, 2024 $671.64M
Stockholders Equity Q2 2025 · Jun 30, 2024 $529.34M
Stockholders Equity Q2 2025 · Mar 31, 2024 $582.53M
Stockholders Equity Q2 2025 · Dec 31, 2023 $442.02M
Current Liabilities Q2 2025 · Jun 30, 2025 $52.59M
Current Liabilities Q2 2025 · Dec 31, 2024 $47.87M
Total Liabilities Q2 2025 · Jun 30, 2025 $67.16M
Total Liabilities Q2 2025 · Dec 31, 2024 $70.76M
Current Assets Q2 2025 · Jun 30, 2025 $578.75M
Current Assets Q2 2025 · Dec 31, 2024 $738.46M
Total Assets Q2 2025 · Jun 30, 2025 $582.32M
Total Assets Q2 2025 · Dec 31, 2024 $742.4M
Net Income Q2 2025 · Jun 30, 2025 −$100.74M
Net Income Q2 2025 · Jun 30, 2025 −$187.65M
Net Income Q2 2025 · Mar 31, 2025 −$86.91M
Net Income Q2 2025 · Jun 30, 2024 −$64.99M
Net Income Q2 2025 · Jun 30, 2024 −$113.54M
Net Income Q2 2025 · Mar 31, 2024 −$48.54M
Operating Income Q2 2025 · Jun 30, 2025 −$106.77M
Operating Income Q2 2025 · Jun 30, 2025 −$200.63M
Operating Income Q2 2025 · Jun 30, 2024 −$72.19M
Operating Income Q2 2025 · Jun 30, 2024 −$128.08M
Shares Diluted Q2 2025 · Jun 30, 2024 63.85M sh
Shares Diluted Q2 2025 · Jun 30, 2024 62.48M sh